

DAFTAR PUSTAKA

1. PDPI, PERKI, PAPDI, PERDATIN, IDAI. *Pedoman Tatalaksana COVID-19*. Edisi 4. PDPI, PERKI, PAPDI, PERDATIN, IDAI; 2022.
2. Indonesia KKR. Situasi Terkini Perkembangan COVID-19. *InfeksiEmerging*. Published online 2021:1-4.
3. Roumier M, Paule R, Groh M, Vallée A. Interleukin-6 Blockade for Severe COVID-19. *MedRxiv*. Published online 2020:4-10. doi:10.1101/2020.04.20.20061861
4. Zhu J, Pang J, Ji P, et al. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. *J Med Virol*. 2019;93(1):1-6. doi:10.1002/jmv.26085
5. Maeda T, Obata R, Rizk D, Kuno T. The association of interleukin-6 value , interleukin inhibitors , and outcomes of patients with COVID - 19 in New York City. *J Med Virol*. 2021;93:463-471. doi:10.1002/jmv.26365
6. Betts BC, Young JW. Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019. *Crit Care Expl*. 2020;2(6):1-4. doi:10.1097/CCE.0000000000000138
7. Khafaie MA, Rahim F. Cross-Country Comparison of Case Fatality Rates of COVID-19/ SARS-COV-2. *Osong Public Heal Res Perspect*. 2020;11(2):74-80. doi:10.24171/j.phrp.2020.11.2.03
8. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7
9. Horby PW, Landray MJ. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. *Lancet*. 2021;397:1637-1645. doi:10.1101/2021.02.11.21249258
10. Coomes EA, Hagbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. *Rev Med Virol*. 2020;30(6):1-9. doi:10.1002/rmv.2141
11. Guillén L, Padilla S, Fernández M, et al. Preemptive interleukin-6 blockade in patients with COVID-19. *Sci Rep*. 2020;10(1):1-9. doi:10.1038/s41598-020-74001-3
12. Kumar S, Nyodu R, Maurya VK, Saxena SK. Morphology, Genome Organization, Replication, and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In: *Coronavirus Disease 2019 (COVID-19)*. Springer Nature Singapore Pte Ltd; 2020:23-31. doi:10.1007/978-981-15-4814-7_3
13. Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. *Trends Immunol*. 2020;41(12):1100-1115. doi:10.1016/j.it.2020.10.004
14. Yang L, Liu S, Liu J, et al. COVID-19: immunopathogenesis and immunotherapeutics. *Signal Transduct Target Ther*. 2020;5(128):1-8. doi:10.1038/s41392-020-00243-2
15. Scheller J, Chalaris A, Schmidt-arra D, Rose-john S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim Biophys Acta*. 11;1813:878-888. doi:10.1016/j.bbamcr.2011.01.034
16. Gur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL-6 : Structure pathophysiological roles and inhibitors. *Bioorg Med Chem*. 20;28(115327):1-17. doi:10.1016/j.bmc.2020.115327



17. Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. *Cold Spring Harb Perspect Biol* 2014;6a016295. 2014;6(a016295):1-16. doi:10.1101/cshperspect.a016295
18. Potere N, Batticciotto A, Vecchié A, et al. The role of IL-6 and IL-6 blockade in COVID-19. *Expert Rev Clin Immunol*. 2021;17(6):601-618. doi:10.1080/1744666X.2021.1919086
19. Camporeale A, Poli V. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? *Front Biosci*. 2012;17(6):2306-2326. doi:10.2741/4054
20. Jones SA, Takeuchi T, Aletaha D, Smolen J, Choy EH, McInnes I. Interleukin 6: The biology behind the therapy. *Considerations Med*. 2018;2:2-6. doi:10.1136/conmed-2018-000005
21. Heinrich PC, Castell J V, Tilo A. Interleukin-6 and the acute phase response. *Biochem J*. 1990;265(3):621-636. doi:10.1042/bj2650621
22. Gruys E, Toussaint MJM, Niewold TA, Koopmans SJ. Acute phase reaction and acute phase proteins. *J Zhejiang Univ Sci*. 2005;6B(11):1045-1056. doi:10.1631/jzus.2005.B1045
23. Huang J, Cheng A, Kumar R, et al. Hypoalbuminemia predicts the outcome of COVID - 19 independent of age and co - morbidity. *J Med Virol*. 2020;92(10):2152-2158. doi:10.1002/jmv.26003
24. Li L, Chen C. Contribution of acute-phase reaction proteins to the diagnosis and treatment of 2019 novel coronavirus disease (COVID-19). *Epidemiol Infect*. 2020;148(e164):1-6. doi:10.1017/S095026882000165X
25. Vogel-gonz M, Tall M, Gemma P, et al. Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection. *Nutr*. 2021;13(562):1-13. doi:10.3390/ nu13020562
26. Sui J, Noubouossie DF, Gandotra S, Cao L. Elevated Plasma Fibrinogen Is Associated With Excessive Inflammation and Disease Severity in COVID-19 Patients. *Front Cell Infect Microbiol*. 2021;11(734005):1-7. doi:10.3389/fcimb.2021.734005
27. Yormaz B, Ergun D, Tulek B, et al. The evaluation of prognostic value of acute phase reactants in the COVID-19. *Bratisl Med J*. 2020;121(9):628-633. doi:10.4149/BLL
28. Zhang B, Zhou X, Zhu C, et al. Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With. *Front Mol Biosci*. 2020;7(157):1-7. doi:10.3389/fmolb.2020.00157
29. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis*. 2020;71(16):2027-2034. doi:10.1093/cid/ciaa344
30. Yang L, Gou J, Gao J, et al. Immune characteristics of severe and critical COVID-19 patients. *Signal Transduct Target Ther*. 2020;5(179):1-3. doi:10.1038/s41392-020-00296-3
31. Gha A, Meurant R, Ardakani A. COVID-19 Serological Tests : How Well Do They Actually Perform? *Diagnostics*. 2020;10(453):1-14. doi:10.3390/diagnostics10070453
32. Maeda K, Mehta H, Drevets DA, Coggeshall KM. IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew matopoiesis and elevate myeloid production. *Blood*. 2010;115(23):4699-06. doi:10.1182/blood-2009-07-230631.
- tansever HS, Becer E. Relationship between IL-6 and COVID-19 : to be nsidered during treatment. *Futur Virol*. 2020;15(12):1-6. doi:10.2217/fvl-20-0168
- uyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, Mcdonald DR.



- Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution! *Clin Immunol.* 2020;216(108459):1-4. doi:10.1016/j.clim.2020.108459
35. Woodruff MC, Ramonell RP, Nguyen DC, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. *Nat Immunol.* 2020;21:1506-1516. doi:10.1038/s41590-020-00814-z
 36. Dienz O, Rincon M. The effects of IL-6 on CD4 T cell responses. 2010;130(1):27-33. doi:10.1016/j.clim.2008.08.018.
 37. Yang R, Masters AR, Fortner KA, et al. IL-6 promotes the differentiation of a subset of naive CD8 + T cells into IL-21 – producing B helper CD8 + T cells. *J Exp Med.* 2016;213(11):2281-2291. doi:10.1084/jem.20160417
 38. Kimura A, Kishimoto T. IL-6: Regulator of Treg/Th17 balance. *Eur J Immunol.* 2010;40:1830-1835. doi:10.1002/eji.201040391
 39. Rupp J, Dreo B, Gütl K, et al. T Cell Phenotyping in Individuals Hospitalized with COVID-19. *J Immunol.* 2022;206:1478-1482. doi:10.4049/jimmunol.2001034
 40. Niculet E, Chioncel V, Elisei AM, et al. Multifactorial expression of IL - 6 with update on COVID - 19 and the therapeutic strategies of its blockade (Review). *Exp Ther Med.* 2021;21(263):1-10. doi:10.3892/etm.2021.9693
 41. Wang H, Wang Z, Cao W, Wu Q, Yuan Y, Zhang X. Regulatory T cells in COVID-19. *Aging Dis.* 2021;12(7):1545-1553. doi:10.14336/AD.2021.0709
 42. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19 : The Current Evidence and Treatment Strategies. *Front Immunol.* 2020;11(1708):1-13. doi:10.3389/fimmu.2020.01708
 43. Bhaskar S, Sinha A, Banach M, Mittoo S. Cytokine Storm in COVID-19 — Immunopathological Mechanisms , Clinical Considerations , and Therapeutic Approaches : The REPROGRAM Consortium Position Paper. *Front Immunol.* 2020;11(1648):1-16. doi:10.3389/fimmu.2020.01648
 44. Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. *J Allergy Clin Immunol.* 2020;146(3):518-534. doi:10.1016/j.jaci.2020.07.001
 45. Rabaan AA, Al-ahmed SH, Muhammad J, Khan A, Sule AA. Role of Inflammatory Cytokines in COVID-19 Patients : A Review on Molecular Mechanisms , Immune Functions , Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. *Vaccines.* 2021;9(436):1-23. doi:10.3390/vaccines9050436
 46. Tang L, Yin Z, Hu Y, Mei H. Controlling Cytokine Storm Is Vital in COVID-19. *Front immunol.* 2020;11(570993):1-14. doi:10.3389/fimmu.2020.570993
 47. Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. *Science (80-).* 2009;368(6490):473-474. doi:10.1126/science.abb8925
 48. Wong CK, Lam CWK, Wu AKL, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory. *Clin Exp Immunol.* 2004;136:95-103. doi:10.1111/j.1365-2249.2004.02415.x
 49. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020;130(5):2620-2629. doi:10.1172/JCI137244
 50. Ding DX, X DX, Dx W, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine.* 2020;55(102763):1-10. doi:10.1016/j.ebiom.2020.102763
 51. Li T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. *J Thromb Hemost.* 2020;18:2103-2109. doi:10.1111/jth.14975



52. Xin Long, Zhang Z, Zou W, et al. Coagulopathy of Patients with COVID-19 is Associated with Infectious and Inflammatory Markers. *Risk Manag Healthc Policy*. 2020;13:1965-1975. doi:10.2147/RMHP.S268238
53. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan , China. *Lancet*. 2020;395:497-506. doi:10.1016/S0140-6736(20)30183-5
54. Zhang D, Zhou X, Yan S, et al. Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU. *Clin Chim Acta*. 2020;510:47-53. doi:10.1016/j.cca.2020.07.002
55. Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019 novel coronavirus. *Lancet*. 2020;8:11-12. doi:10.1016/S2213-2600(20)30071-0
56. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18:844-847. doi:10.1111/jth.14768
57. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020;180(7):934-943. doi:10.1001/jamainternmed.2020.0994
58. Wang J, Yang X, Li Y, Huang J, Jiang J, Su N. Specific cytokines in the inflammatory cytokine storm of patients with COVID - 19 - associated acute respiratory distress syndrome and extrapulmonary multiple - organ dysfunction. *Virology*. 2021;18(117):1-12. doi:10.1186/s12985-021-01588-y
59. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan , China : a retrospective cohort study. *Lancet*. 2020;395:1054-1062. doi:10.1016/S0140-6736(20)30566-3
60. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID - 19 based on an analysis of data of 150 patients from Wuhan , China. *Intensive Care Med*. 2020;46(5):846-848. doi:10.1007/s00134-020-05991-x
61. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;6736(20):19-20. doi:10.1016/S0140-6736(20)30628-0
62. Matthay MA, Zemans RL. The Acute Respiratory Distress Syndrome: Pathogenesis and Treatment. *Annu Rev Pathol*. 2011;6:147-163. doi:10.1146/annurev-pathol-011110-130158
63. Pierrakos C, Karanikolas M, Scolletta S, Karamouzou V. Acute Respiratory Distress Syndrome : Pathophysiology and Therapeutic Options. *J Clin Med Res*. 2011;4(1):7-16. doi:10.4021/jocmr761w
64. Robba C, Battaglini D, Pelosi P, Rocco PRM. Multiple organ dysfunction in SARS-CoV-2 : MODS-CoV-2. *Expert Rev Respir Med*. 2020;14(9):1-4. doi:10.1080/17476348.2020.1778470
65. Scherger S, Henao-Martínez A, Franco-Paredes C, Shapiro L. Rethinking interleukin-6 blockade for treatment of COVID-19. *Med Hypotheses*. 2020;144(110053):1-4. doi:10.1016/j.mehy.2020.110053
66. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet*. 2020;8:420-422. doi:10.1016/S2213-2600(20)30076-X
67. Le DM Del, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med*. 2020;26(10):1636-1643. doi:10.1038/s41591-020-1051-9
68. Luo Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data



- determinations for patients with the severe COVID - 19. *J Med Virol*. Published online 2020:1-6. doi:10.1002/jmv.25770
69. Grifoni E, Valoriani A, Francesco Cei F, Lamanna R. Interleukin-6 as prognosticator in patients with COVID-19. *J Infect*. 2020;81:452-482. doi:10.1016/j.jinf.2020.06.008
 70. Herold T, Jurinovic V, Arnreich C, Lipworth BJ. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J Allergy Clin Immunol*. 2020;146(1):128-136. doi:10.1016/j.jaci.2020.05.008
 71. Aziz M, Fatima R, Assaly R. Elevated interleukin - 6 and severe COVID - 19: A meta - analysis. *J Med Virol*. 2020;92:2283-2285. doi:10.1002/jmv.25948
 72. Avila-nava A, Cortes-telles A, Torres-erazo D, Stephanie L. Serum IL-6 : A potential biomarker of mortality among SARS-CoV-2 infected patients in Mexico. *Cytokine*. 2020;143(155543):1-7. doi:10.1016/j.cyto.2021.155543
 73. Zhang J, Hao Y, Ou W, et al. Serum interleukin - 6 is an indicator for severity in 901 patients with SARS - CoV - 2 infection : a cohort study. *J Transl Med*. 2020;18(406):1-8. doi:10.1186/s12967-020-02571-x
 74. Chen X, Zhao B, Qu Y, et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019. *Clin Infect Dis*. 2020;71:1935-1942. doi:10.1093/cid/ciaa449
 75. Pandolfi L, Fossali T, Frangipane V, et al. Broncho-alveolar inflammation in COVID-19 patients : a correlation with clinical outcome. *BMC Pulm Med*. 2020;20(301):1-10. doi:10.1186/s12890-020-01343-z
 76. Ji P, Zhu J, Zhong Z, et al. Association of elevated inflammatory markers and severe COVID-19: A meta-analysis. *Medicine (Baltimore)*. 2020;99(47):1-12. doi:10.1097/MD.00000000000023315
 77. Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U. Circulating Levels of Interleukin-6 and Interleukin-10 , But Not Tumor Necrosis Factor-Alpha , as Potential Biomarkers of Severity and Mortality for COVID-19 : Systematic Review with Meta-analysis. *J Clin Immunol*. 2020;41(1):11-22. doi:10.1007/s10875-020-00899-z
 78. Laguna-goya R, Utrero-rico A, Talayero P, Lasa-lazaro M, Aguado JM, Martinez-lopez J. IL-6 – based mortality risk model for hospitalized patients with COVID-19. *J Allergy Clin Immunol*. 2020;146(4):799-807. doi:10.1016/j.jaci.2020.07.009
 79. Zhou J, He W, Liang J, et al. Association of Interleukin-6 Levels with Morbidity and Mortality in Patients with Coronavirus Disease 2019 (COVID-19). *Jpn J Infect Dis*. 2021;74(4):293-298. doi:10.7883/yoken.JJID.2020.463
 80. Shekhawat J, Gauba K, Gupta S, Purohit P. Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm. *Indian J Clin Biochem*. 2021;36(4):440-450. doi:10.1007/s12291-021-00989-8
 81. Abate BB, Kassie AM, Kassaw MW, Aragie TG. Sex difference in coronavirus disease (COVID-19): a systematic review and meta - analysis. *BMJ Open*. 2020;10(10):1-10. doi:10.1136/bmjopen-2020-040129
 82. Fortunato F, Martinelli D, Caputo S Lo, et al. Sex and gender differences in COVID-19 : an Italian local register- - based study. *BMJ Open*. 2021;11(10):1-7. doi:10.1136/bmjopen-2021-051506
 83. Jankhe V, Aboelnasr A, Pahal P, Qadir N, Kiran S, Sekaran B. Age , comorbidities , and Mortality Correlation in COVID-19 Patients : A Review. *Arab J Respir Infect*. 2020;4(1):1-6. doi:10.18297/jri/vol4/iss1/69



84. Green MS, Nitzan D, Schwartz N, Niv Y, Peer V. Sex differences in the case-fatality rates for COVID-19 — A comparison of the age-related differences and consistency over seven countries. *PLoS One*. 2021;16(4):1-13. doi:10.1371/journal.pone.0250523
85. Zhang H, Wu Y, He Y, et al. Age-Related Risk Factors and Complications of Patients With COVID-19 : A Population-Based Retrospective Study. *Front Med*. 2022;8:1-12. doi:10.3389/fmed.2021.757459
86. Setiadi W, Rozi IE, Safari D, et al. Prevalence and epidemiological characteristics of COVID-19 after one year of pandemic in Jakarta and neighbouring areas , Indonesia: A single center study. *PLoS One*. 2022;17(5):1-9. doi:10.1371/journal.pone.0268241
87. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7
88. Susanto AD, Rozaliyani A, Prasetyo B, et al. Epidemiological and Clinical Features of COVID-19 Patients at National Emergency Hospital Wisma Atlet Kemayoran , Jakarta ,. *Kesmas J Kesehat Masy Nas (National Public Heal Journal)*. 2021;16(1):11-16. doi:10.21109/kesmas.v0i0.5233
89. Kaleemi R, Hilal K, Id AA, et al. The association of chest radiographic findings and severity scoring with clinical outcomes in patients with COVID-19 presenting to the emergency department of a tertiary care hospital in Pakistan. *PLoS One*. 2021;16(1):1-11. doi:10.1371/journal.pone.0244886
90. Rostamian A, Ghazanfari T, Arabkheradmand J, Ghaffarpour S, Salehi M. Interleukin-6 as a Potential Predictor of COVID-19 Disease Severity in Hospitalized Patients and its Association With Clinical Laboratory Routine Tests. *Immunoregulation*. 2020;3(1):29-36. doi:10.32598/IMMUNOREGULATION.3.1.4
91. Sartini S, Massobrio L, Cutuli O, et al. Role of SatO2 , PaO2 / FiO2 Ratio and PaO2 to Predict Adverse Outcome in COVID-19 : A Retrospective , Cohort Study. *Int J Environ Res Public Heal*. 2021;18(11534):1-13. doi:10.3390/ijerph182111534
92. Jain V, Kumar P, Panda PK, Suresh M, Kaushal K. Utility of IL-6 in the Diagnosis , Treatment and Prognosis of COVID-19 Patients : A Longitudinal Study. *Vaccines*. 2022;10(1786):1-8. doi:10.3390/vaccines10111786
93. Zayed NE, Abbas A, Lutfy SM. Criteria and potential predictors of severity in patients with COVID-19. *Egypt J Bronchol*. 2022;16(11):1-8. doi:10.1186/s43168-022-00116-y
94. Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severities : A Multicenter Study of Clinical Features. *Am J Respir Crit Care Med*. 2020;201(11):1380-1388. doi:10.1164/rccm.202002-0445OC
95. Kumar A, Aggarwal R, Khanna P, et al. Correlation of the SpO2/FiO2 (S/F) ratio and the PaO2/FiO2 (P/F) ratio in patients with COVID-19 pneumonia. *Med Intensiva*. 2022;46(7):408-410. doi:10.1016/j.medin.2021.10.005
96. Putu N, Putra P, Listyoko AS, Christanto A. PaO2, SaO2, dan Rasio PaO2/FiO2 Sebagai Prediktor Derajat Keparahan Pasien COVID-19 Rawat Inap. *J Indon Med Assoc*. 2020;70(12):253-259.
97. MG, Hussain FI, Kumar A, Priyadarshani D, Sidhwani K, Zehra K. Frequency of COVID-19 Complications and Their Outcomes in Patients Admitted to a Tertiary Care Hospital in Karachi. *J Hunan Univ (Natural Sci)*. 2021;48(12):57-64.
98. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382:1708–1720.



- doi:10.1056/NEJMoa2002032
99. Shappell CN, Klompas M, Kanjilal S, Chan C, Rhee C. Prevalence , Clinical Characteristics , and Outcomes of Sepsis Caused by Severe Acute Respiratory Syndrome Coronavirus 2 Versus Other Pathogens in Hospitalized Patients With. *Crit Care Explor.* 2022;4(5):1-8. doi:10.1097/CCE.0000000000000703
 100. Ng WH, Tipih T, Burt FJ, Taylor A. Comorbidities in SARS-CoV-2 Patients : a Systematic Review and Meta-Analysis. *ASM J.* 2021;12(1):1-12. doi:10.1128/mBio.03647-20
 101. Lau ES, McNeill JN, Paniagua SM, et al. Sex differences in inflammatory markers in patients hospitalized with COVID-19 infection : Insights from the MGH COVID-19 patient registry. *PLoS One.* 2021;16(4):1-9. doi:10.1371/journal.pone.0250774
 102. Hu H, Pan H, Li R, He K, Zhang H, Liu L. Increased Circulating Cytokines Have a Role in COVID-19 Severity and Death With a More Pronounced Effect in Males : A Systematic Review and Meta-Analysis. *Front Pharmacol.* 2022;13(802228):1-15. doi:10.3389/fphar.2022.802228
 103. Oktavia N, Rofinda ZD, Kedokteran F, Indonesia UA. Comparison in levels of interleukin 6, ferritine, and neutrophil - lymphocyte ratio in covid-19 patients treated in ICU and non-ICU. *J Profesi Med J Kedokt dan Kesehat.* 2022;16(2):120-127. doi:10.33533/jpm.v16i2.4891
 104. Zhu A, Liu M, Li Y, et al. Age- and Severity-Associated Humoral Immunity Response in COVID-19 Patients : A Cohort Study from Wuhan , China. *J Clin Med.* 2022;11(5974):1-16. doi:10.3390/jcm11195974
 105. Luporini RL, Rodolpho JMDA, Tatsuo L, et al. IL-6 and IL-10 are associated with disease severity and higher comorbidity in adults with COVID-19. *Cytokine.* 2021;143:1-5.
 106. Ananda RYD, Hudari NKH, Bahar E. Correlation of Interleukin-6 Levels with Clinical Features and Chest X-Ray Imaging in Coronavirus Disease-19 (COVID-19) Patients at Dr . Mohammad Hoesin General Hospital Palembang. *Biosci Med J Biomed Transl Res.* 2022;6(5):1799-1805. doi:10.37275/bsm.v6i5.515
 107. Aykal G, Esen H, Seyman D. Could IL-6 predict the clinical severity of COVID-19? *Turkish J Biochem.* 2021;46(5):499-507. doi:10.1515/tjb-2021-0020
 108. Lashin AH, El-ghafar AOA, Mahmoud AM, Shewi ME El. Value of Interleukin 6 in Assessment of the Disease Severity in Patients with COVID-19 Infection without Preexisting Comorbidities. *Benha Med J.* 2023;40(6):74-86. doi:10.21608/BMFJ.2023.185224.1738
 109. Nandkeoliar MK, Gupta V, Thakur RK, et al. Radio-Clinical Findings in COVID-19 Patients : A Hallmark of Systemic Inflammation. *J Coast Life Med.* 2023;11(1):837–844.
 110. Bhandari S, Rankawat G, Singh A, Wadhwani D, Patel B. Evaluation of Interleukin - 6 and its Association with the Severity of Disease in COVID - 19 Patients. *Indian J Med Spec.* 2020;11(3):132-136. doi:10.4103/INJMS.INJMS_63_20
 111. Liu T, Zhang J, Yang Y, et al. The role of interleukin- 6 in monitoring severe se of coronavirus disease 2019. *EMBO Mol Med.* 2020;12(e12421):1-12. i:10.15252/emmm.202012421
 - Ren L, Zhang Z, Wei X, Cai Y, Yao W, Wang M. Association between tokine profiles and lung injury in COVID-19 pneumonia. *Respir Res.* 20;21(201):1-8. doi:10.1186/s12931-020-01465-2
 - ddie S, Ziff O, Chou MKL, et al. Laboratory biomarkers associated with



- COVID-19 severity and management. *Clin Immunol*. 2020;221(108614):1-5. doi:10.1016/j.clim.2020.108614
114. Zhu J, Pang J, Ji P, et al. Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis. *J Med Virol*. 2021;93(1):35-37. doi:10.1002/jmv.26085
 115. Donoso-navarro E, Gómez IA, Bernabeu-andreu FA. IL-6 and Other Biomarkers associated with Poor Prognosis in a Cohort of Hospitalized Patients with COVID-19 in Madrid. *Biomark Insights*. 2021;16:1-8. doi:10.1177/11772719211013363
 116. Huang L, Zhao X, Qi Y, et al. Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019. *Cell Mol Immunol*. 2020;17(10):1092–1094. doi:10.1038/s41423-020-00522-6
 117. Talwar D, Kumar S, Acharya S, Raisinghani N, Madaan S, Hulkoti V. Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital : A Cross-sectional Study. *Indian J Crit Care Med*. 2022;26(1):39–42. doi:10.5005/jp-journals-10071-24075
 118. Eichhorn T, Huber S, Weiss R, et al. Infection with SARS-CoV-2 Is Associated with Elevated Levels of IP-10 , MCP-1 , and IL-13 in Sepsis Patients. *Diagnostics*. 2023;13(6):1-12. doi:10.3390/diagnostics13061069
 119. Zhang C, Wu Z, Li J, Zhao H, Wang G. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int J Antimicrob Agents*. 2020;55(105954):1-7. doi:10.1016/j.ijantimicag.2020.105954
 120. Gosangi B, Rubinowitz AN, Irugu D, Gange C, Bader A, Cortopassi I. COVID - 19 ARDS : a review of imaging features and overview of mechanical ventilation and its complications. *Emerg Radiol*. 2022;29:23-34. doi:10.1007/s10140-021-01976-5
 121. Brandi N, Ciccarese F, Rimondi MR, et al. An Imaging Overview of COVID-19 ARDS in ICU Patients and Its Complications : A Pictorial Review. *Diagnostics*. 2022;12(846):1-22. doi:10.3390/diagnostics12040846
 122. Whittle JS, Pavlov I, Sacchetti AD, Atwood C, Rosenberg MS. Respiratory support for adult patients with COVID-19. *JACEP Open*. 2020;1:95-101. doi:10.1002/emp2.12071
 123. Wilcox SR, Condella A. Emergency Department Management of Severe Hypoxemic Respiratory Failure in Adults With COVID-19. *J Emerg Med*. 2021;60(6):729-742. doi:10.1016/j.jemermed.2020.12.014
 124. Franco C, Facciolo N, Tonelli R, et al. Feasibility and clinical impact of out-of-ICU non- invasive respiratory support in patients with COVID-19 related pneumonia. *Eur Respir J*. 2020;56(5):1-35. doi:10.1183/13993003.02130-2020
 125. Tufan ZK, Kayaaslan B, Mer M. COVID-19 and Sepsis. *Turkish J Med Sci*. 2021;51:3301-3311. doi:10.3906/sag-2108-239
 126. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. *Int J Antimicrob Agents J*. 2020;56:1-4. doi:10.1016/j.ijantimicag.2020.106051
 127. Santis V De, Corona A, Vitale D, et al. Bacterial infections in critically ill patients with SARS - 2 - COVID - 19 infection : results of a prospective observational multicenter study. *Infection*. 2022;50(1):139-148. doi:10.1007/s15010-021-01661-2
 - addaloni E, Buzzetti R. Covid-19 and diabetes mellitus : unveiling the interaction of two pandemics. *Diabetes Metab Res Rev*. 2020;36(7):19-20. doi:10.1002/dmrr.3321
 - io W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and



- prognosis of COVID-19. *Diabetes Metab Res Rev*. 2020;36(7):1-9. doi:10.1002/dmrr.3319
130. Kaeley N, Mahala P, Walia R, Arora P, Dhingra V. Electrocardiographic abnormalities in patients with COVID - 19 pneumonia and raised interleukin - 6. *J Fam Med Prim Care*. 2022;1(10):5902-5908. doi:10.4103/jfmpc.jfmpc
 131. Alzamily AA, Al-Delfi MN, Al-Barqaw AR. A Role for Inflammatory IL-6 In the Development of Coronary Artery Disease: A Case Control Study at Al-Qadisiyah Governorate, Iraq. *Mil Med Sci Lett*. 2022;91(4):293-304. doi:10.31482/mmsl.2022.005
 132. Cruz AS, Mendes-frias A, Oliveira AI, Dias L, Castro AG, Silvestre R. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. *Front Immunol*. 2021;12(613422):1-10. doi:10.3389/fimmu.2021.613422
 133. Guirao JJ, Cabrera CM, Jim N, Rinc L, Urrea M. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. *Mol Immunol*. 2020;128:64-68. doi:10.1016/j.molimm.2020.10.006
 134. Mandel M, Harari G, Gurevich M, Achiron A, Bank B. Cytokine prediction of mortality in COVID19 patients. *Cytokine*. 2020;134(155190):1-4. doi:10.1016/j.cyto.2020.155190
 135. Santos WG dos. Natural history of COVID-19 and current knowledge on treatment therapeutic options. *Biomed Pharmacother*. 2020;129:1-18. doi:10.1016/j.biopha.2020.110493
 136. Romagnoli S, Peris A, Gaudio AR De, Geppetti P. SARS-CoV-2 and COVID-19: From the Bench to the Bedside. *Physiol Rev*. 2020;100:1455-1466. doi:10.1152/physrev.00020.2020
 137. Manson JJ, Crooks C, Naja M, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. *Lancet Rheumatol*. 2020;2:e594–602. doi:10.1016/S2665-9913(20)30275-7
 138. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection – a review of immune changes in patients with viral pneumonia. *Emerg Microbes Infect*. 2020;9:727-732. doi:10.1080/22221751.2020.1746199
 139. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. *J Infect*. 2020;80:607-613.
 140. Lio KU, Rali P. Coagulopathy in COVID-19. *Lung India*. 2021;38(1):53-57. doi:10.4103/lungindia.lungindia
 141. Roquetaillade D, Roquetaillade C De, Bredin S, et al. Timing and causes of death in severe COVID - 19 patients. *Crit Care*. 2021;25(224):1-8. doi:10.1186/s13054-021-03639-w





KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK. TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 108/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 10 Februari 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23020078	No Sponsor Protokol	
Peneliti Utama	dr. Agus Alim	Sponsor	
Judul Peneliti	ANALISIS KADAR INTERLEUKIN-6 (IL-6) SERUM TERHADAP KESINTASAN PASIEN COVID-19		
No Versi Protokol	1	Tanggal Versi	6 Februari 2023
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☒ Exempted ☐ Expedited ☐ Fullboard Tanggal	Masa Berlaku 10 Februari 2023 sampai 10 Februari 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan Laporan akhir setelah Penelitian berakhir
- Menyerahkan Laporan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Menyerahkan Laporan pelanggaran peraturan yang ditentukan

